Stock listing
gettex:TG40 Oxurion NV Aktie
German listing (gettex) of Oxurion NV · home listing Euronext:OXUR
Follow Oxurion NV into a list and get an email when it puts out news.
Home listing price · EURONEXT:OXUR
€0.0010 EUR 0.0000 (0.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:OXUR
- Day range
- €0.0010 – €0.0014 EURNov 20, 2026
- Volume
- 4.58M sharesNov 20, 2026
- Market cap
- €232,005 EURAt the close on Nov 20, 2026 · price × 232.0M shares outstanding
- 52-week range
- €0.0006 – €0.0118 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €3,102 EURMedian day 688,163 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:OXUR · Home | €0.0010 EUR | 0.0000 (0.0%) | 4,575,649 | €0.0010 | €0.0014 | €0.0010 | €0.0010 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:OXUR · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0014 | €0.0010 | 4,575,649 | |
| €0.0010 | +0.0002 | +25.0% | €0.0008 | €0.0012 | €0.0008 | 12,461,813 | |
| €0.0008 | +0.0002 | +33.3% | €0.0008 | €0.0008 | €0.0006 | 3,475,558 | |
| €0.0006 | -0.0002 | -25.0% | €0.0006 | €0.0008 | €0.0006 | 1,050,429 | |
| €0.0008 | +0.0002 | +33.3% | €0.0008 | €0.0008 | €0.0006 | 688,163 | |
| €0.0006 | -0.0002 | -25.0% | €0.0008 | €0.0010 | €0.0006 | 5,333,812 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0006 | 3,690,709 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0006 | 290,164 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0006 | 2,540,867 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0006 | 6,942,060 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0006 | 1,257,066 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0006 | 195,525 | |
| €0.0008 | +0.0002 | +33.3% | €0.0008 | €0.0008 | €0.0006 | 12,331,414 | |
| €0.0006 | -0.0002 | -25.0% | €0.0008 | €0.0008 | €0.0006 | 9,120 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0008 | 941,000 | |
| €0.0008 | +0.0002 | +33.3% | €0.0008 | €0.0010 | €0.0008 | 20,320,212 | |
| €0.0006 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0006 | 1,183,577 | |
| €0.0006 | -0.0002 | -25.0% | €0.0008 | €0.0008 | €0.0006 | 515,638 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0008 | 116,500 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0008 | 116,500 | |
| €0.0008 | 0.0000 | 0.0% | €0.0008 | €0.0008 | €0.0006 | 4,046,200 | |
| €0.0008 | 0.0000 | 0.0% | €0.0006 | €0.0008 | €0.0006 | 349,555 | |
| €0.0008 | +0.0002 | +33.3% | €0.0008 | €0.0008 | €0.0006 | 350,356 | |
| €0.0006 | -0.0004 | -40.0% | €0.0010 | €0.0010 | €0.0006 | 17,321,410 | |
| €0.0010 | +0.0002 | +25.0% | €0.0010 | €0.0010 | €0.0010 | 146,690 | |
| €0.0008 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0008 | 115,001 | |
| €0.0008 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0008 | 260,234 | |
| €0.0008 | -0.0002 | -20.0% | €0.0010 | €0.0010 | €0.0008 | 303,996 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0008 | 183,000 | |
| €0.0010 | -0.0002 | -16.7% | €0.0012 | €0.0012 | €0.0008 | 735,950 | |
| €0.0012 | 0.0000 | 0.0% | €0.0012 | €0.0012 | €0.0008 | 1,631,383 | |
| €0.0012 | 0.0000 | 0.0% | €0.0012 | €0.0012 | €0.0010 | 517,029 | |
| €0.0012 | +0.0002 | +20.0% | €0.0012 | €0.0012 | €0.0010 | 1,275,586 | |
| €0.0010 | 0.0000 | 0.0% | €0.0012 | €0.0012 | €0.0010 | 9,731,721 | |
| €0.0010 | -0.0006 | -37.5% | €0.0012 | €0.0012 | €0.0010 | 21,836,869 | |
| €0.0016 | 0.0000 | 0.0% | €0.0012 | €0.0016 | €0.0012 | 136,344 | |
| €0.0016 | +0.0002 | +14.3% | €0.0012 | €0.0016 | €0.0012 | 1,440,276 | |
| €0.0014 | +0.0002 | +16.7% | €0.0012 | €0.0016 | €0.0012 | 742,283 | |
| €0.0012 | -0.0006 | -33.3% | €0.0016 | €0.0018 | €0.0012 | 6,322,878 | |
| €0.0018 | 0.0000 | 0.0% | €0.0018 | €0.0018 | €0.0014 | 159,399 | |
| €0.0018 | 0.0000 | 0.0% | €0.0016 | €0.0018 | €0.0014 | 2,757,034 | |
| €0.0018 | +0.0002 | +12.5% | €0.0020 | €0.0020 | €0.0016 | 2,279,496 | |
| €0.0016 | -0.0002 | -11.1% | €0.0022 | €0.0022 | €0.0016 | 3,216,867 | |
| €0.0018 | 0.0000 | 0.0% | €0.0020 | €0.0026 | €0.0018 | 7,819,121 | |
| €0.0018 | -0.0004 | -18.2% | €0.0028 | €0.0028 | €0.0018 | 5,376,678 | |
| €0.0022 | -0.0006 | -21.4% | €0.0026 | €0.0026 | €0.0020 | 3,384,344 | |
| €0.0028 | 0.0000 | 0.0% | €0.0028 | €0.0028 | €0.0024 | 245,800 | |
| €0.0028 | +0.0004 | +16.7% | €0.0026 | €0.0028 | €0.0026 | 41,666 | |
| €0.0024 | -0.0002 | -7.7% | €0.0026 | €0.0026 | €0.0024 | 2,200 | |
| €0.0026 | 0.0000 | 0.0% | €0.0024 | €0.0026 | €0.0024 | 112,829 | |
| €0.0026 | +0.0002 | +8.3% | €0.0024 | €0.0026 | €0.0024 | 13,302 | |
| €0.0024 | -0.0002 | -7.7% | €0.0026 | €0.0026 | €0.0024 | 117,970 | |
| €0.0026 | -0.0002 | -7.1% | €0.0024 | €0.0026 | €0.0024 | 1,158,950 | |
| €0.0028 | 0.0000 | 0.0% | €0.0028 | €0.0028 | €0.0024 | 3,185,125 | |
| €0.0028 | +0.0002 | +7.7% | €0.0026 | €0.0028 | €0.0026 | 67,002 | |
| €0.0026 | 0.0000 | 0.0% | €0.0028 | €0.0028 | €0.0026 | 1,640 | |
| €0.0026 | 0.0000 | 0.0% | €0.0026 | €0.0028 | €0.0026 | 360,234 | |
| €0.0026 | 0.0000 | 0.0% | €0.0026 | €0.0026 | €0.0026 | 158,176 | |
| €0.0026 | 0.0000 | 0.0% | €0.0030 | €0.0030 | €0.0026 | 292,570 | |
| €0.0026 | 0.0000 | 0.0% | €0.0026 | €0.0028 | €0.0026 | 124,644 | |
| €0.0026 | -0.0002 | -7.1% | €0.0028 | €0.0028 | €0.0026 | 1,133,367 | |
| €0.0028 | -0.0002 | -6.7% | €0.0032 | €0.0032 | €0.0026 | 381,834 | |
| €0.0030 | +0.0004 | +15.4% | €0.0026 | €0.0036 | €0.0026 | 4,631,424 | |
| €0.0026 | 0.0000 | 0.0% | €0.0026 | €0.0028 | €0.0026 | 111,270 | |
| €0.0026 | -0.0002 | -7.1% | €0.0024 | €0.0028 | €0.0024 | 281,105 | |
| €0.0028 | 0.0000 | 0.0% | €0.0028 | €0.0028 | €0.0028 | 46,500 | |
| €0.0028 | 0.0000 | 0.0% | €0.0028 | €0.0028 | €0.0028 | 100,000 |
Splits
1 split · EURONEXT:OXUR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10000 | Consolidation |
- Ticker
- gettex:TG40
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Sep 30, 2026
Interim Financial Report — Half-year results as of 30 June 2026 (EN)
Latest news
Interim Financial Report — Half-year results as of 30 June 2026 (EN)
Sep 30, 2026
Closed €0.0016 (+14.3%) on Oct 1, 2026
Oxurion: Oxurion Publishes First Half 2026 Results
Sep 30, 2026
Closed €0.0016 (+14.3%) on Oct 1, 2026
Oxurion: Oxurion enters into exclusive negotiations to acquire the business and assets of Eclevar, a MedTech-focused CRO
Sep 30, 2026
Closed €0.0014 (+16.7%) on Sep 30, 2026
Oxurion: Oxurion expands its clinical research platform through strategic biometrics partnership between Axiodis CRO and KYomed INNOV
Jul 21, 2026
Closed €0.0024 (-7.7%) on Jul 21, 2026
Oxurion: Oxurion achieves another milestone in the expansion of the Exagis platform with the commercial launch of its eTMF module
Jul 6, 2026
Closed €0.0028 (0.0%) on Jul 7, 2026
Oxurion: Oxurion launches a software-driven growth strategy with Exagis
Jun 8, 2026
Closed €0.0032 (0.0%) on Jun 9, 2026
Oxurion: Oxurion Announces Results on the Annual Shareholders’ Meeting of 1 June 2026
Jun 3, 2026
Closed €0.0030 (-16.7%) on Jun 4, 2026
Oxurion: Oxurion expands its capabilities to address the growing demand for GLP-1 and peptide clinical research services
Jun 2, 2026
Closed €0.0036 (+5.9%) on Jun 3, 2026
Oxurion - Termination of discussions for the French CRO project (LOI dated 13/10/25) and prioritization of the international target (LOI dated 19/03/26)
Jun 2, 2026
Closed €0.0034 (-5.6%) on Jun 2, 2026
Publication Annual Report - Annual Shareholders Meeting
Apr 30, 2026
Closed €0.0040 (+5.3%) on May 4, 2026
Oxurion NV on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 15 in the last 12 months · 15 in all · newest Sep 30, 2026 · oldest 2025
- Decks
- 9 decks · latest Jun 7, 2022
Where Oxurion NV is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:OXUR · Home listing | Euronext | Belgium | EUR |
| LSE:0G99 | LSE | United Kingdom | EUR |
| LS Exchange:A40H8H | LS Exchange | Germany | EUR |
| gettex:TG40 · This page | gettex | Germany | EUR |
| Lang & Schwarz:A40H8H | Lang & Schwarz | Germany | EUR |
| Frankfurt:TG40 | Frankfurt | Germany | EUR |
| Stuttgart:TG40 | Stuttgart | Germany | EUR |
| Aquis:OXURB | Aquis | United Kingdom | EUR |
| Aquis:OXURB | Aquis | United Kingdom | EUR |
| Turquoise:OXURB | Turquoise | United Kingdom | EUR |
Valuation
EV/sales 21.1× against a median of 1.3×: 8th lowest of 9 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €11.71M EUR
- P/E
- Loss
- EV/sales
- 21.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 87.8%
- Operating margin
- −653.9%
- Net margin
- −671.7%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Oxurion NV · EURONEXT:OXUR | US$254,615 | US$12.85M | n/a | 21.1× | n/a | n/a | −671.7% | n/a | n/a |
| Innovotech Inc. · TSXV:IOT | US$2.66M | US$2.51M | n/a | 1.0× | n/a | 1.5× | −21.1% | 0.1× | 0.39 |
| Qlife Holding AB · OMXSTO:QLIFE | US$2.49M | US$2.88M | n/a | 34.1× | n/a | 9.6× | n/a | 3.1× | n/a |
| Physiomics PLC · LSE:PYC | US$2.46M | US$1.91M | n/a | 1.6× | n/a | 3.6× | −74.1% | 0.0× | n/a |
| 20/20 BioLabs, Inc. · NASDAQ:AIDX | US$2.10M | −US$1.01M | n/a | −0.5× | n/a | 3.4× | −317.8% | 0.9× | 1.41 |
| Bluejay Diagnostics, Inc. · NASDAQ:BJDX | US$1.90M | −US$5.43M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.71 |
| Accustem Sciences Inc · OTC:ACUT | US$1.90M | US$1.88M | n/a | n/a | n/a | n/a | n/a | n/a | 0.19 |
| InVitro International · OTC:IVRO | US$1.87M | US$644,260 | 29.6× | 0.8× | 14.0× | 1.1× | 8.2% | 0.0× | 0.17 |
| Co-Diagnostics, Inc. · NASDAQ:CODX | US$1.36M | US$2.21M | n/a | 2.6× | n/a | 0.1× | n/a | 0.2× | 2.16 |
| Prostatype Genomics AB · OMXSTO:PROGEN | US$1.36M | US$1.32M | n/a | 13.3× | n/a | 2.1× | n/a | 0.0× | n/a |
| Virax Biolabs Group Limited · NASDAQ:VRAX | US$446,402 | −US$5.66M | n/a | −455× | n/a | 0.1× | n/a | 0.1× | 1.38 |
| Median of the others | US$1.90M | US$1.60M | 29.6× | 1.3× | 14.0× | 1.5× | −47.6% | 0.1× | 1.38 |
Team and board
Officers
| Officer | Role |
|---|---|
| Pascal Ghoson | CEO & CFO, Executive Director |
Board
| Director | Role |
|---|---|
| Charles Paris de Bollardière | Chairman of the Board |
| James Hartmann | Independent Non-Executive Director |
| Nelly Souleymane | Independent Non-Executive Director |
| Pascal Ghoson | CEO & CFO, Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2025 | Nov 28, 2025 | −1.9% |
| Q2 2025 | Sep 30, 2025 | +4.2% |
| Quarter to Mar 31, 2025 | Apr 11, 2025 | 0.0% |
| Q4 2024 | Mar 31, 2025 | −20.0% |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | −6.5% |
| Q2 2024 | Sep 30, 2024 | −12.8% |
| Quarter to Mar 31, 2024 | Apr 15, 2024 · After close | 0.0% |
| Quarter to Sep 30, 2023 | Oct 20, 2023 | −30.0% |
| Q2 2023 | Sep 29, 2023 · After close | +8.3% |
| Q1 2023 | May 4, 2023 | −4.0% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 24, 2023 · After close | +2.0% |
| Q3 2022 | Oct 21, 2022 | −30.1% |
| Q2 2022 | Sep 7, 2022 · Before open | −11.2% |
| Quarter to Mar 31, 2022 | May 12, 2022 | +2.1% |
| Q4 2021 | Mar 25, 2022 · After close | +5.1% |
| Q3 2021 | Oct 14, 2021 | +0.4% |
| Q2 2021 | Sep 9, 2021 · After close | 0.0% |
| Q1 2021 | May 6, 2021 | −2.0% |
| Q4 2020 | Mar 17, 2021 · After close | +1.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (June 2022) | Technical | 12 slides | Jun 7, 2022 |
| Investor Presentation (May 2022) | Investor deck | 21 slides | May 2022 |
| Investor Presentation (February 2022) | Investor deck | 45 slides | February 2022 |
| Investor Presentation (January 2022) | Investor deck | 32 slides | January 2022 |
| Investor Presentation (November 2021) | Investor deck | 35 slides | November 2021 |
| Angiogenesis, Exudation, and Degeneration 2020 | Conference | 19 slides | Feb 8, 2020 |
| Investor Presentation (September 2019) | Investor deck | 43 slides | September 2019 |
| FLORetina 2019 | Conference | 16 slides | June 2019 |
| ThromboGenics — Investor Presentation (May 2017) | Investor deck | 46 slides | May 2017 |
Financings
| Raise | Date |
|---|---|
| Convertible bonds Announced: convertible Buyers: Atlas Capital Markets (Subscription agreement for convertible bonds totalling €30 million in 12 tranches of €2.5 million) Use of proceeds: Launch investment strategy in digital assets, specifically Bitcoin and Ethereum | Dec 1, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 555.0K | 3.00K | 263.0K | 595.0K | 1.13M | 2.08M | 3.95M | 5.32M | 5.81M | 7.10M |
| Cost of revenue | 68.0K | 43.0K | 159.0K | 513.0K | 612.0K | 550.0K | 5.03M | 3.35M | 2.58M | 6.88M |
| Gross profit | 487.0K | -40.0K | 104.0K | 82.0K | 516.0K | 1.53M | -1.09M | 1.97M | 3.23M | 224.0K |
| Research and development | 1.85M | 1.24M | 9.99M | 16.0M | 20.7M | 22.1M | 23.7M | 29.6M | 24.0M | 24.7M |
| Selling, general and administrative | 1.92M | 2.01M | 2.82M | 5.98M | 7.15M | 5.49M | 6.41M | 6.35M | 6.23M | 6.52M |
| Operating income | -3.63M | 382.0K | -12.1M | -22.9M | -28.5M | -28.6M | -37.9M | -39.2M | -29.5M | -34.2M |
| Depreciation and amortization | 68.0K | 142.0K | 268.0K | 353.0K | 77.0K | 194.0K | 2.77M | 3.63M | 3.83M | 7.68M |
| EBITDA | -3.56M | 524.0K | -11.8M | -22.6M | -28.4M | -28.4M | -35.1M | -35.6M | -25.6M | -26.6M |
| Interest expense | 9.00K | 218.0K | 7.27M | 9.38M | 1.27M | 408.0K | 55.0K | 24.0K | 31.0K | 36.0K |
| Income before tax | -3.70M | 122.0K | -19.0M | -31.7M | -29.6M | -28.6M | -52.1M | -38.8M | 22.6M | -60.4M |
| Income tax | 10.0K | 3.00K | 3.00K | 7.00K | 3.00K | 0 | 17.0K | 10.0K | 14.0K | -22.0K |
| Net income | -3.73M | 119.0K | -19.0M | -31.7M | -29.2M | -28.0M | -51.8M | -38.5M | 22.8M | -60.3M |
| Earnings per share, basic | -0.13 | 0.09 | -114.82 | -0.37 | -0.77 | -0.75 | -13,535.39 | -10,058.56 | 6,226.23 | -16,483.74 |
| Earnings per share, diluted | -0.37 | -0.77 | -0.75 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 430.0K | 455.0K | 1.62M | 3.50M | 9.74M | 24.5M | 42.5M | 64.7M | 56.2M | 58.3M |
| Short-term investments | 50.0K | 95.0K | 247.0K | 288.0K | 10.4M | 20.5M | 49.6M | 21.8M | ||
| Receivables | 381.0K | 2.36M | 1.01M | 825.0K | 974.0K | 1.41M | 2.29M | 2.74M | 2.63M | 5.18M |
| Inventory | 0 | 5.00K | 60.0K | 85.0K | 20.0K | 1.04M | 2.20M | 2.61M | ||
| Current assets | 1.81M | 3.58M | 2.74M | 7.11M | 13.4M | 27.1M | 57.0M | 91.1M | 124.3M | 91.4M |
| Property, plant and equipment | 57.0K | 99.0K | 120.0K | 230.0K | 2.55M | 614.0K | 991.0K | 1.74M | ||
| Goodwill | 182.0K | 0 | 0 | 0 | 0 | |||||
| Total assets | 3.83M | 5.70M | 6.55M | 12.0M | 18.9M | 34.3M | 65.0M | 114.9M | 150.4M | 121.6M |
| Accounts payable | 2.54M | 4.52M | 4.94M | 5.04M | 4.98M | 4.38M | 4.72M | 5.05M | 3.30M | 5.94M |
| Current liabilities | 16.2M | 16.6M | 19.6M | 12.3M | 10.9M | 7.69M | 10.4M | 9.55M | 17.1M | 11.8M |
| Long-term debt | 0 | 3.23M | 8.43M | 0 | ||||||
| Total debt | 11.4M | 11.3M | 12.3M | 8.02M | 12.1M | 1.10M | 2.23M | |||
| Total liabilities | 16.5M | 16.8M | 19.7M | 16.6M | 20.0M | 9.24M | 11.7M | 9.55M | 17.1M | 11.8M |
| Shareholders' equity | -12.9M | -11.1M | -13.2M | -4.58M | -1.08M | 25.2M | 53.2M | 104.9M | 132.6M | 109.8M |
| Shares outstanding | 28.0M | 1.27M | 165.2K | 8.50K | 3.84K | 3.83K | 3.83K | 3.83K | 3.66K | 3.66K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.71M | -2.07M | -9.77M | -19.4M | -27.0M | -27.1M | -31.1M | -31.1M | 26.3M | -20.3M |
| Capital spending | 0 | 0 | -1.00K | -59.0K | -32.0K | -119.0K | -133.0K | -195.0K | -246.0K | -572.0K |
| Free cash flow | -1.71M | -2.07M | -9.77M | -19.4M | -27.0M | -27.2M | -31.2M | -31.3M | 26.0M | -20.9M |
| Cash from investing | -270.0K | 84.0K | 72.0K | 111.0K | 407.0K | 10.1M | 10.0M | 29.1M | -27.6M | -15.1M |
| Cash from financing | 1.95M | 815.0K | 7.82M | 13.0M | 11.8M | -931.0K | -843.0K | 84.0K | 9.99M | -6.00K |
| Share buybacks | 92.0K | 10.0M | ||||||||
| Change in cash | -25.0K | -1.17M | -1.87M | -6.27M | -14.8M | -17.9M | -22.2M | -1.52M | 7.92M | -35.1M |
Cap table
Built by 6ix from Oxurion NV’s releases · as of Dec 1, 2025
- Common shares
- 232,004,731
- Fully diluted
- 232,004,731
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 232,004,731 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 232,004,731 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Charles Paris de Bollardière | Chairman of the Board · Since at least Sep 30, 2026 |
| James Hartmann | Independent Non-Executive Director · Since at least Nov 6, 2026 |
| Nelly Souleymane | Independent Non-Executive Director · Since at least Nov 6, 2026 |
| Pascal Ghoson | CEO & CFO, Executive Director · Since at least Sep 30, 2026 |
Log in to ask 6ix AI your own questions about Oxurion NV.